Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funding to advance a HER2-targeted, dual ...

(PDCs) demonstrate tumor-selective delivery and potent anticancer activityPreclinical data show robust efficacy as ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

(NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM ...

Frazier Life Sciences launched Callio Therapeutics, a cancer startup headquartered in Seattle and Singapore. Frazier led ...

Callio Therapeutics, a biotechnology company, has launched with the closing of a $187.0 million Series A financing round.

The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 ...

Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report ...

ArriVent BioPharma, Inc. ( ($AVBP) ) has released its Q4 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to ...

Suven Pharmaceuticals Chairman discusses global outsourcing, growth strategies, and Phase 3 pipeline expansion in interview ...

Elevation Oncology (NASDAQ:ELEV – Get Free Report) will likely be issuing its quarterly earnings data before the market opens ...